Johnson & Johnson (JNJ) Stock Analysis
A structured research starting point for Johnson & Johnson — a diversified healthcare giant and one of the most defensive blue chips. Price history, key metrics, the questions great investors would ask, and community sentiment. Educational only.
Price Chart
View recent prices as a table
| Date | Close |
|---|---|
| 2026-11-09 | $282.11 |
| 2026-11-06 | $276.22 |
| 2026-11-05 | $272.32 |
| 2026-11-04 | $276.32 |
| 2026-11-03 | $266.17 |
| 2026-11-02 | $270.56 |
| 2026-10-30 | $273.20 |
| 2026-10-29 | $275.20 |
| 2026-10-28 | $271.04 |
| 2026-10-27 | $268.73 |
Overview
Johnson & Johnson is a diversified healthcare company spanning innovative pharmaceuticals and medical devices. Following the spin-off of its consumer-health unit, it is focused on higher-margin prescription drugs and surgical technologies.
Its appeal is defensiveness and predictability: healthcare demand is relatively insensitive to economic cycles. The central debate is its drug pipeline, patent cliffs, and ongoing litigation exposure.
Key Metrics at a Glance
Approximate reference figures for education. Always verify against the latest filings before any decision.
Business Segments
Approximate share of revenue. Verify against the latest annual report.
Bull Case vs Bear Case
- Highly defensive, recession-resistant healthcare demand.
- Diversified across drugs and medical devices.
- Decades-long record of growing dividends.
- Patent cliffs can erode high-margin drug revenue.
- Ongoing litigation creates uncertainty.
- Drug-pricing pressure and regulation weigh on margins.
Key Dates
How the Masters Would Frame It
Each legendary investor asks different questions. Use these lenses as a structured checklist — not as buy or sell signals.
| Investor | Their lens | Key question they would ask |
|---|---|---|
| Warren Buffett | Durable moat & predictability | Is the pipeline and scale durable enough to predict cash flows a decade out? |
| Charlie Munger | Quality & diversification | Does diversification protect earnings, or dilute the best businesses? |
| Peter Lynch | Growth vs. price | Does the drug pipeline offer enough growth for a defensive stalwart? |
| Benjamin Graham | Margin of safety | What protection does the dividend and stability provide at this price? |
Community & market-attention modules4
Community Sentiment
How does the community feel about this stock right now? Cast your vote.
Value × Sentiment Map
Where this stock sits on two axes: how its price compares to its own 1-year average (cheap ↔ expensive), and how the crowd feels on X right now (bearish ↔ bullish). Value investing rewards looking where the crowd is not.
Could not build the map right now. Please try again later.
7-Day TikTok Buzz
How much this stock has been talked about on TikTok over the past week — daily video count, weighted by engagement.
Bars: daily public TikTok videos mentioning this stock (via TikHub), scaled by engagement. Line: daily closing price (via EODHD) over the same days — see whether chatter leads or follows the price. Delayed and approximate, for information only — not advice.
Social Media Buzz
What X/Twitter is saying about this stock right now — auto-scored bullish vs bearish from recent cashtag posts.
Latest News & Announcements
Recent earnings coverage and market headlines for this stock, synced automatically.
- Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- ISRG Gains 7.8% in 6 Months: Will the Share Price Recovery Continue?
- J&J gets into psychedelic treatments with backing of Delix Therapeutics
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- What Is Johnson & Johnson (JNJ) Signaling With Two Key Trial Wins?
- Johnson & Johnson Showcases Positive Trial Data For Key Autoimmune Therapies
- J&J Backs Psychedelic-Inspired Biotech in $100 Million Round
- Johnson & Johnson Says Icotyde in Psoriatic Arthritis Disease Meets Primary Endpoint in Phase 3 Study
Headlines aggregated from public sources via EODHD. For information only, not advice.
Frequently Asked Questions
Is Johnson & Johnson a good stock to buy?
We do not give buy or sell advice. The useful question is whether JNJ fits your goals and whether the price reflects realistic growth. Use the master frameworks above as a checklist.
How does Johnson & Johnson make money?
It earns most of its revenue from prescription pharmaceuticals and medical devices sold to providers, payers, and patients worldwide.
Does JNJ pay a dividend?
Yes. JNJ has a long record of paying and raising its dividend for decades, making it a favorite of income investors.
What are the main risks for JNJ?
Commonly cited considerations include patent cliffs, pipeline setbacks, drug-pricing pressure, and litigation exposure.
Free email digests when there is new analysis, earnings coverage, and valuation context. No spam.
We respect your privacy. Unsubscribe anytime.Compare With Other Stocks
Related Stocks
Quick Facts
Fast answers to common questions about this stock:
Related Guides & Glossary
Learn the frameworks used on this page:
Not financial advice
This page is an educational research starting point built from public information. It is not investment advice, not a recommendation to buy or sell, and figures may be delayed or approximate. Always do your own research.
Research this company with master frameworks inside the app:
Get the App